WHAT IS CLAIMED IS:

1. A recombinant oncolytic adenovirus comprising a first nucleotide sequence encoding a first therapeutic transgene selected from human endostatin and human angiostatin inserted between the start codon of E1b-19K and the start codon of E1b-55K.

2. The recombinant oncolytic adenovirus of claim 1, wherein the recombinant oncolytic adenovirus is a type 5 adenovirus (Ad5).

3. The recombinant oncolytic adenovirus of claim 1 or claim 2, wherein the recombinant oncolytic adenovirus comprises a second nucleotide sequence encoding a second therapeutic transgene selected from human endostatin and human angiostatin, wherein the first therapeutic transgene and the second therapeutic transgene do not express the same protein.

4. The recombinant oncolytic adenovirus of any one of claims 1-3, wherein the recombinant oncolytic adenovirus further comprises an E3 deletion.

5. The recombinant oncolytic adenovirus of claim 3, wherein the second therapeutic transgene is inserted between the stop codon of pVIII and the start codon of Fiber.

6. The recombinant oncolytic adenovirus of any one of claims 1-5, wherein the recombinant oncolytic adenovirus comprises a nucleotide sequence encoding an amino acid sequence having 95% sequence identity to SEQ ID NO: 7, a nucleotide sequence encoding an amino acid sequence having 95% sequence identity to SEQ ID NO: 8, a nucleotide sequence having 95% sequence identity to SEQ ID NO: 9, a nucleotide sequence encoding an amino acid sequence having 95% sequence identity to an amino acid sequence selected from SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, a nucleotide sequence encoding an amino acid sequence having 95% sequence identity to SEQ ID NO: 17, or a nucleotide sequence having 95% sequence identity to SEQ ID NO: 18.

7. The recombinant oncolytic adenovirus of any one of claims 1-6, wherein the first and/or second therapeutic transgenes are not operably linked to an exogenous promoter sequence or wherein neither of the therapeutic transgenes are operably linked to an exogenous promoter sequence.

8. The recombinant oncolytic adenovirus of any one of claims 1-7, wherein the recombinant oncolytic adenovirus further comprises a deletion of a Pea3 binding site.

9. The recombinant oncolytic adenovirus of any one of claims 1-7, wherein the recombinant oncolytic adenovirus further comprises a deletion of a E2F binding site, wherein the recombinant oncolytic adenovirus does not comprise a deletion of a Pea3 binding site.

10. The recombinant oncolytic adenovirus of any one of claims 1-9, wherein the recombinant oncolytic adenovirus comprises an E1a promoter having a deletion of a functional TATA box.

11. The recombinant oncolytic adenovirus of any one of claims 1-10, wherein the recombinant oncolytic adenovirus comprises an E1a promoter having a deletion of a functional CAAT box.

12. The recombinant oncolytic adenovirus of any one of claims 1-11, wherein the recombinant oncolytic adenovirus selectively expresses endostatin and/or angiostatin in the hyperproliferative cell.

13. A pharmaceutical composition comprising the recombinant oncolytic adenovirus of any one of claims 1-12 and at least one pharmaceutically acceptable carrier or diluent.

14. Use of the pharmaceutical composition of claim 13 in the manufacture of a medicament for inhibiting growth of a tumor or treating a cancer in a subject.

15. Use of the pharmaceutical composition of claim 13 in the manufacture of a medicament for treating cancer in a subject in need thereof, wherein the pharmaceutical composition further comprises an anti-angiogenic agent.

16. The use of claim 15, wherein the cancer is selected (i) from anal cancer, basal cell carcinoma, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoma, cholangiocarcinoma, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, gastroesophageal cancer, gastrointestinal (GI) cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, gynecologic cancer, head and neck cancer, hematologic cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, merkel cell carcinoma, mesothelioma, neuroendocrine cancer, non-small cell lung cancer, ovarian cancer, pancreatic

cancer, pediatric cancer, prostate cancer, renal cell carcinoma, sarcoma, skin cancer, small cell lung cancer, squamous cell carcinoma of the skin, stomach cancer, testicular cancer and thyroid cancer, (ii) from melanoma, squamous cell carcinoma of the skin, basal cell carcinoma, head and neck cancer, breast cancer, anal cancer, cervical cancer, non-small cell lung cancer, mesothelioma, small cell lung cancer, renal cell carcinoma, prostate cancer, gastroesophageal cancer, colorectal cancer, testicular cancer, bladder cancer, ovarian cancer, liver cancer, hepatocellular carcinoma, cholangiocarcinoma, brain and central nervous system cancer, thyroid cancer, endometrial cancer, neuroendocrine cancer, lymphoma, leukemia, merkel cell carcinoma, gastrointestinal stromal tumors, multiple myeloma, uterine cancer, a sarcoma, kidney cancer, ocular cancer, and pancreatic cancer, (iii) from gastroesophageal cancer, non-small cell lung cancer, colorectal cancer, ovarian cancer, leukemia, cervical cancer, brain and central nervous system cancer, kidney cancer, a sarcoma, lymphoma, ocular cancer, and von Hippel-Lindau disease, or (iv) from brain and central nervous system cancer, kidney cancer, ocular cancer, a sarcoma, liver cancer, lymphoma, leukemia, and a germ cell tumor.

17. The use of claim 15 or claim 16, wherein the anti-angiogenic agent is selected from aflibercept, an anti-VEGF antibody, sunitinib, pazopanib, sorafenib, regorafenib, vandetanib, cabozantinib, axitinib, tivozanib, linifanib, pegaptanib, spironolactone, indomethacin, thalidomide, interleukin-12, an anti-FGF antibody, a tyrosine kinase inhibitor, an interferon, suramin, a suramin analog, somatostatin, and a somatostatin analog.

18. The use of any one of claims 15-17, wherein the pharmaceutical composition further comprises a second recombinant oncolytic adenovirus, wherein the second recombinant oncolytic adenovirus (i) comprises a nucleotide sequence encoding a polypeptide, or a fragment thereof, selected from acetylcholine, an androgen-receptor, an anti-PD-1 antibody heavy chain and/or light chain, an anti-PD-L1 antibody heavy chain and/or light chain, BORIS/CTCFL, BRAF, CD19, CD20, CD30, CD80, CD86, CD137, CD137L, CD154, CEA, DKK1/Wnt, EGFRvIII, FGF, gp100, Her-2/neu, ICAM, IL-1, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-17, IL-23A/p19, p40, IL-24, IL-27, IL-27A/p28, IL-27B/EBI3, IL-35, interferon-gamma, KRAS, MAGE, MAGE-A3, MART1, melan-A, mesothelin, MUC-1, NY-ESO-1, Podocalyxin (Podxl), p53, TGF-β, a TGF-β Trap, thymidine kinase, and tyrosinase, (ii) comprises a nucleotide sequence encoding a polypeptide, or a fragment thereof, selected from acetylcholine, an

androgen-receptor, an anti-PD-1 antibody heavy chain and/or light chain, an anti-PD-L1 antibody heavy chain and/or light chain, BORIS/CTCFL, BRAF, CD19, CD20, CD30, CD80, CD86, CD137, CD137L, CD154, CEA, DKK1/Wnt, EGFRvIII, FGF, gp100, Her-2/neu, ICAM, IL-1, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-23A/p19, p40, IL-24, interferon-gamma, KRAS, MAGE, MAGE-A3, MART1, melan-A, mesothelin, MUC-1, NY-ESO-1, Podocalyxin (Podxl), p53, TGF-β, a TGF-β Trap, thymidine kinase, and tyrosinase, or (iii) comprises a nucleotide sequence encoding a cancer antigen derived from 9D7, androgen receptor, a BAGE family protein, β-catenin, BING-4, BRAF, BRCA1/2, a CAGE family protein, calcium-activated chloride channel 2, CD19, CD20, CD30, CDK4, CEA, CML66, CT9, CT10, cyclin-B1, EGFRvIII, Ep-CAM, EphA3, fibronectin, a GAGE family protein, gp100/pme117, Her-2/neu, HPV E6, HPV E7, Ig, immature laminin receptor, a MAGE family protein, MART-1/melan-A, MART2, MC1R, mesothelin, a mucin family protein, NY-ESO-1/LAGE-1, P.polypeptide, p53, podocalyxin (Podxl), PRAME, a ras family proteins, prostate specific antigen, a SAGE family protein, SAP-1, SSX-2, survivin, TAG-72, TCR, telomerase, TGF-βRII, TRP-1, TRP-2, tyrosinase, or a XAGE family protein.

19. Use of the pharmaceutical composition of claim 13 in the manufacture of a medicament for lowering blood pressure in a subject and/or increasing nitric oxide (NO) production in a subject.

20. The pharmaceutical composition of claim 13 for use in therapy.